Skip to content

The Efficacy and Safety of Glutamine Combined with Prednisone Acetate in Children with Primary Nephrotic Syndrome

The Efficacy and Safety of Glutamine Combined with Prednisone Acetate in Children with Primary Nephrotic Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500103360
Enrollment
Unknown
Registered
2025-05-28
Start date
2025-04-02
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary nephrotic syndrome

Interventions

The glutamine group:None
Control group:None

Sponsors

Shanghai Children’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 14 Years

Inclusion criteria

Inclusion criteria: 1 Met the diagnostic criteria for nephrotic syndrome in the 2017 KDIGO Guidelines; 2 First onset; 3 Complete remission can be achieved after 4-6 weeks of initial treatment; 4 <14 years old.

Exclusion criteria

Exclusion criteria: 1 Patients with diseases of other organs; 2 Children who have received hormonal, immunosuppressive or biologic treatment before admission; 3 secondary nephrotic syndrome (such as lupus nephritis, purpura nephritis, diabetic nephropathy, etc.), IgA nephropathy, congenital nephropathy; 4 Cases with incomplete data.

Design outcomes

Primary

MeasureTime frame
Hormone therapy effect;The time required for urine protein to turn negative;Frequency of disease recurrence;

Secondary

MeasureTime frame
Number of infections;

Countries

China

Contacts

Public ContactYulin Kang

Shanghai Children’s Hospital

kangyl@shchildren.com.cn+86 182 2199 2381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026